These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18701573)

  • 1. Defining the natural history of MS: the need for complete data and rigorous definitions.
    Tremlett H; Zhao Y; Devonshire V
    Mult Scler; 2008 Sep; 14(8):1142-3; author reply 1144-7. PubMed ID: 18701573
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining the natural history of MS: the need for complete data and rigorous definitions.
    Confavreux C
    Mult Scler; 2008 Apr; 14(3):289-91. PubMed ID: 18420777
    [No Abstract]   [Full Text] [Related]  

  • 3. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
    Trojano M; Paolicelli D; Bellacosa A; Cataldo S
    Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression in familial and nonfamilial MS.
    Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J
    Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender change and its impact on the course of multiple sclerosis.
    Reske D; Haupt WF; Petereit HF
    Acta Neurol Scand; 2006 May; 113(5):347-9. PubMed ID: 16629772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of multiple sclerosis.
    Deshpande R; Kremenchutzky M; Rice GP
    Adv Neurol; 2006; 98():1-15. PubMed ID: 16400823
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural history of multiple sclerosis: risk factors and prognostic indicators.
    Vukusic S; Confavreux C
    Curr Opin Neurol; 2007 Jun; 20(3):269-74. PubMed ID: 17495619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive multiple sclerosis: The treatment gap.
    Humphries C
    Nature; 2012 Apr; 484(7393):S10. PubMed ID: 22509511
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple sclerosis.
    Hawker K; Frohman E
    Prim Care; 2004 Mar; 31(1):201-26. PubMed ID: 15110166
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.
    Eriksson M; Andersen O; Runmarker B
    Mult Scler; 2003 Jun; 9(3):260-74. PubMed ID: 12814173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapsing-remitting and primary progressive MS have the same cause(s)--the neuropathologist's view: 1.
    Lassmann H
    Mult Scler; 2013 Mar; 19(3):266-7. PubMed ID: 23426169
    [No Abstract]   [Full Text] [Related]  

  • 12. Relapsing-remitting and primary progressive MS have the same cause(s)--the neuropathologist's view: commentary.
    Farrell M
    Mult Scler; 2013 Mar; 19(3):270. PubMed ID: 23426171
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple sclerosis: Cognition and saccadic eye movements.
    Fielding J; Kilpatrick T; Millist L; White O
    J Neurol Sci; 2009 Feb; 277(1-2):32-6. PubMed ID: 18977003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
    Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
    Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients.
    Debouverie M; Laforest L; Van Ganse E; Guillemin F;
    Mult Scler; 2009 Feb; 15(2):251-7. PubMed ID: 19181774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of relapses in multiple sclerosis.
    Vollmer T
    J Neurol Sci; 2007 May; 256 Suppl 1():S5-13. PubMed ID: 17346747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of depression with disease course in multiple sclerosis.
    Zabad RK; Patten SB; Metz LM
    Neurology; 2005 Jan; 64(2):359-60. PubMed ID: 15668442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N
    Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple sclerosis: progression rate and severity in a multicenter cohort from Algeria.
    Hecham N; Nouioua S; Sifi Y; Toubal N; Aissa LA; Hattab S; Batsi D; Hamimed A; Berkane F; Oudrer N; Aidi A; Abrouk S; Daoudi S; Hamri A; Assami S; Tazir M
    Mult Scler; 2014 Dec; 20(14):1923-4. PubMed ID: 25122474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.